Soliqua 100/33 (lixisenatide/insulin glargine) / Zealand Pharma, Sanofi - LARVOL DELTA

iGlarlixi for the simplification of more complex insulin regimens in type 2 diabetes patients with good glycaemic control. (PubMed, Front Endocrinol (Lausanne)) - "Furthermore, the subgroup with large BMI and low insulin dose at baseline had stable BMI trajectory (vs a decrease in all other subgroups). Simplification of complex regimens with iGlarLixi in patients with good glycaemic control maintains glycaemic control with weight loss, reduced risk of hypoglycaemia, and lower insulin dose over 42 months."

Journal • Observational data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Use of fixed-ratio combination of basal insulin and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Asians with type 2 diabetes. (PubMed, Prim Care Diabetes) - "In this narrative review, we summarized the efficacy and safety data from randomized controlled trials using iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL (iGlar) and lixisenatide (Lixi), a short acting GLP-1 RA, studied widely in Asians. We discussed the guidelines on the use of this fixed-ratio combination illustrated by real-world case studies in older Asian adults with young-onset type 2 diabetes."

Journal • Review • Cardiovascular • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Efficacy of de-escalation from complex insulin regimens to once-daily iGlarLixi in adults with type 2 diabetes: a pooled analysis of Soli-SWITCH and IDEAL studies (EASD 2026) - P4 | "This pooled analysis suggests there are clinical benefits in transitioning from complex insulin regimens to a once-daily treatment with iGlarLixi."

Retrospective data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

iGlarLixi provides early glycaemic improvement without an increase in hypoglycaemia after switching from premixed insulins in adults with type 2 diabetes: a post hoc analysis of Soli-SWITCH (EASD 2026) - "Adults with T2D who switched from PI to iGlarLixi using the Soli-SWITCH titration algorithm achieved timely glycaemic improvement which was sustained to Week 12. Hypoglycaemia data at Weeks 0-4 and Weeks 5-8 indicate that this early glycaemic control did not increase the risk of hypoglycaemia during the initial titration period. These findings support iGlarLixi as an effective treatment option when switching from PI, with a favourable safety profile when appropriately titrated and monitored."

Clinical • Retrospective data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Post-prandial glucose excursions with iGlarLixi versus monocomponents and glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: a post hoc pooled analysis (EASD 2026) - P3 | "In this pooled analysis, iGlarLixi demonstrated consistent reductions in post-prandial glucose excursions over a 24-h period in adults with T2D, with more participants achieving post-meal glucose targets."

Retrospective data • Diabetes • Metabolic Disorders • Severe Hypoglycemia • Type 2 Diabetes Mellitus

Effectiveness, safety and healthcare resource utilisation of iGlarLixi in people with type 2 diabetes uncontrolled on basal insulin: results from the prospective real-world SOLI-ADVANCE study in Saudi Arabia (EASD 2026) - "iGlarLixi demonstrated statistically significant reductions in HbA1c in PwT2D inadequately controlled on BI. The treatment was associated with decreased hypoglycemia rates and body weight benefits. These real-world findings from Saudi Arabia support iGlarLixi as an effective and well-tolerated treatment intensification option."

Clinical • HEOR • Real-world • Real-world evidence • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli-D Study. (PubMed, Diabetes Obes Metab) - "iGlarLixi provides improved glycaemic control at lower insulin doses with reduced risk of hypoglycaemia in Chinese adults with suboptimally controlled T2D on OADs, regardless of baseline age, disease duration or HbA1c."

Journal • Retrospective data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Beyond Glycemic Control: Real-World 12-Month Effects of Insulin Glargine/Lixisenatide on Weight, Endogenous Insulin Secretion, and Albuminuria. (PubMed, J Clin Med) - "Early treatment responses may serve as practical predictors of long-term outcomes, supporting a personalized approach to diabetes management. These findings should be interpreted in the context of concomitant therapies and comorbidities that may have influenced metabolic and renal outcomes in routine clinical practice."

Journal • Real-world evidence • Diabetes • Metabolic Disorders • Renal Disease • Type 2 Diabetes Mellitus

A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - P4 | N=105 | Completed | Sponsor: Sanofi | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents (clinicaltrials.gov) - P4 | N=1316 | Recruiting | Sponsor: Shanghai Zhongshan Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Real-world evidence • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Impact of iGlarLixi on Glycaemic Control Depth and Variability in Asian Pacific People With Type 2 Diabetes: A Post Hoc Analysis of LixiLan-O-AP and LixiLan-L-CN. (PubMed, Diabetes Obes Metab) - "iGlarLixi improves dTITR, GV, and PPG control versus iGlar or Lixi in Asian Pacific individuals with T2D."

Journal • Retrospective data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Real-World Effectiveness and Safety of iGlarLixi in People With Type 2 Diabetes in LATAM Region: A Subanalysis of the SUCCESS Study. (PubMed, Diabetes Obes Metab) - No abstract available

Journal • Real-world evidence • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus Combined With Metabolic Dysfunction-associated Steatotic Liver Disease (clinicaltrials.gov) - P4 | N=36 | Active, not recruiting | Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Enrolling by invitation ➔ Active, not recruiting

Enrollment closed • Diabetes • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Type 2 Diabetes Mellitus

Cost-effectiveness of iGlarLixi vs. IDegAsp in individuals with type 2 diabetes: a BRAVO model-based evaluation. (PubMed, Front Public Health) - P3 | "Within the threshold of $40,344/QALY, the probability of iGlarLixi being cost-effective compared with IDegAsp was 83%. In individuals with type 2 diabetes inadequately controlled by oral antihyperglycemic agents, treatment with iGlarLixi is associated with superior long-term clinical outcomes and lower healthcare costs compared to IDegAsp in the Chinese healthcare setting."

HEOR • Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

IGlarLixi Improves PPG and DTIR in Asian People with T2D (PwT2D): Post Hoc Pooled Analysis of Ph3 Studies (ADA 2026) - "Introduction and Objective: Ph3 studies have compared iGlarLixi vs individual components (LixiLan-O-AP, LixiLan-L-CN) or IDegAsp (SoliD) in Asian PwT2D. This analysis showed consistent PPG and dTIR benefits over 24h with iGlarLixi vs comparators in Asian people with T2D."

Retrospective data • Metabolic Disorders • Type 2 Diabetes Mellitus

Impact of IGlarLixi on Glycemic Variability (GV): A Participant-Level Exploratory Pooled Analysis of the Global LixiLan Clinical Trial Program (ADA 2026) - "iGlarLixi demonstrated consistent improvements in PPG excursions and GV versus Gla-100 and GLP-1 RA therapies in PwT2D."

Retrospective data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Impact of Time of Injection on the Efficacy and Safety of iGlarLixi Versus IDegAsp in Chinese People With Type 2 Diabetes: Exploratory Analysis of the Soli-D Study. (PubMed, Diabetes Obes Metab) - "Once-daily iGlarLixi, injected before breakfast, was associated with improved HbA1c control and greater average 2-h PPG reductions compared with IDegAsp, regardless of injection time, in Chinese adults with T2D suboptimally controlled with OADs."

Journal • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Semaglutide in patients with hidradenitis suppurativa and obesity: a prospective study on dermatologic, metabolic, and weight-independent anti-inflammatory effects (ECO 2026) - "The figure illustrates the change in mean HbA1c levels before and after initiation of insulin glargine/lixisenatide therapy... Semaglutide treatment in patients with HS and obesity improved weight, body composition, metabolic and inflammatory profiles, and dermatologic and psychological status. Several clinical and inflammatory benefits persisted after adjustment for weight loss, supporting potential weight-independent anti-inflammatory effects of semaglu-tide in HS. Conflicts of interest: None disclosed Funding: No funding to report"

Clinical • CNS Disorders • Depression • Dermatology • Genetic Disorders • Hidradenitis Suppurativa • Immunology • Obesity

SLIM Study: Simplified Insulin Management with Glargine/ Lixisenatide in Participants Living with Overweight or Obesity and Type 2 Diabetes (ECO 2026) - "Insulin glargine/lixisenatide provides clinically meaningful glycemic improvement while mitigating insulin-associated weight gain in individuals with T2DM and overweight or obesity. This dual metabolic benefit supports its use as an effective and pragmatic insulin strategy in this high-risk population. Conflicts of Interest & Funding: no fundings were obtained and no conflict of interest in this study"

Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A LIFETIME COST-UTILITY ANALYSIS OF IGLARLIXI VERSUS IDEGASP IN TYPE 2 DIABETES IN TURKIYE (ISPOR 2026) - "iGlarLixi is a cost-effective option compared to iDegAsp for uncontrolled T2D in Turkiye,delivering additional life years and QALYs at an acceptable cost.Given the favorable cost-effectiveness of iGlarLixi in patients below the current BMI ≥35 reimbursement cutoff,policymakers could broaden their perspective in the reimbursement restrictions to enhance patient access to newer treatments"

HEOR • Cardiovascular • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 23-26 October 2023 (European Medicines Agency) - "EMA’s safety committee (PRAC) has concluded that the available evidence does not support a causal association between the Glucagon-Like Peptide-1 Receptor Agonists (GLP-1) - exenatide, liraglutide, dulaglutide, semaglutide, and lixisenatide - and cancer of the thyroid (a small gland in the front and lower part of the neck which makes and releases hormones)....The MAHs for liraglutide- (including Victoza, Saxenda, Xultophy), semaglutide- (including Ozempic, Rybelsus, Wegovy), exenatide- (including Bydureon, Byetta), dulaglutide- (i.e.Trulicity) and lixisenatide- (including Lyxumia, Suliqua) containing products should continue to monitor these events closely, including any new publications, as part of their pharmacovigilance activities and report any new evidence on this issue in their Periodic Safety Update Reports (PSURs)."

European regulatory • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Efficacy and safety of switching to iGlarLixi from premixed insulin therapy in patients with type 2 diabetes: A real-world experience. (PubMed, Diabet Med) - "Switching from premixed insulin to iGlarLixi is a safe and effective strategy to simplify therapy and improve glycaemic management. Insulin resistance may influence response."

Journal • Real-world evidence • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Comparative efficacy and safety of three fixed-ratio combination products in type 2 diabetes: A network meta-analysis. (PubMed, J Diabetes Investig) - "Among the three fixed-ratio combination products, IDegLira appears most effective for glycemic control (in terms of HbA1c and FPG reduction), whereas IDegAsp demonstrates the best safety profile regarding incidence of TEAEs."

Journal • Retrospective data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

IMPACT OF TIME OF INJECTION COMPARING IGLARLIXI VS IDEGASP IN CHINESE PEOPLE WITH T2D: EXPLORATORY ANALYSIS OF SOLID STUDY (ATTD 2026) - P3 | "iGlarLixi confirmed better glycaemic control and body weight benefits with lower insulin doses and less hypoglycaemia risk vs IDegAsp regardless of IDegAsp injection time. Funded by Sanofi. Previously presented at ADA and EASD."

Hypoglycemia • Type 2 Diabetes Mellitus

EARLY GLYCAEMIC IMPROVEMENT WHEN SWITCHING TO IGLARLIXI FROM PREMIXED INSULINS (PI) IN ADULTS WITH TYPE 2 DIABETES (T2D): A POST HOC ANALYSIS OF SOLI-SWITCH (ATTD 2026) - P4 | "In adults with T2D who switched from PI to iGlarLixi, glycaemic control improved in the first weeks of transitioning (Weeks 0–3) and continued to improve to Week 12. Funded by Sanofi. Previously presented at ADA and EASD"

Clinical • Retrospective data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus